Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas

Genetic Vaccines and Therapy

Volumn 3, Issue , 2005, Pages

  Carralot, Jean Philippe ^a,b   Weide, Benjamin ^c   Schoor, Oliver ^b   Probst, Jochen ^a,b   Scheel, Birgit ^a   Teufel, Regina ^a   Hoerr, Ingmar ^a   Garbe, Claus ^c   Rammensee, Hans Georg ^b   Pascolo, Steve ^a,b  

^a CureVac GmbH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; COMPLEMENTARY RNA; MESSENGER RNA; TRANSCRIPTOME; TUMOR ANTIGEN; TUMOR VACCINE;

ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA LIBRARY; DNA MICROARRAY; GENE AMPLIFICATION; GENE CONSTRUCT; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC CONSERVATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MELANOMA; METASTASIS; MOLECULAR CLONING; OPEN READING FRAME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZATION; RECOMBINANT PLASMID; RNA TRANSCRIPTION; SEQUENCE ANALYSIS; VACCINATION;

BACTERIA (MICROORGANISMS);

EID: 27344431884     PISSN: 14790556     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-3-6     Document Type: Article

References (51)

1. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolitic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
2. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994, 91:3515-3519.
3. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994, 180:35-42.
4. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appell E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection. PNAS 1994, 91:6458-6462.
5. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993, 178:489-495.
6. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA: Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994, 54:3124-3126.
7. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994, 179:921-930.
8. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. PNAS 1997, 94:1914-1918.
9. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jaeger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, T. B: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219-230.
10. Cebon J, Jaeger E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, Gibbs S, Chen Q, Karbach J, Jackson H, MacGregor DP, Sturrock I S, Vaughan H, Maraskovsky E, Neumann A, Hoffman E, Sherman ML, Knuth A: Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immunity 2003, 3:7-25.
11. Chen Q, Jackson H, Shackleton M, Parente P, Hopkins W, Sturrock S, MacGregor D, Maraskovsky E, Tai TY, Dimopoulos N, Masterman KA, Luke T, Davis ID, Chen W, Cebon J: Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immunity 2005, 5:5-12.
12. Ferrone S, Finerty JF, Jaffee EM, Nabel GJ: How much longer will tumour cells fool the immune system? Immunology Today 2000, 21:70-72.
13. Gilboa E: The makings of a tumor rejection antigen. Immunity 1999, 11:263-270.
14. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. The Journal of Clinical Investigation 2002, 109:409-417.
15. Granstein RD, Ding W, Ozawa H: Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 2000, 114:632-636.
16. Jaeger E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996, 66:470-476.
17. Jaeger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997, 71:142-147.
18. Kerkmann-Tucek A, Banat GA, Cochlovius B, Zoller M: Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination. Int J Cancer 1998, 77:114-122.
19. Singluff CLJ, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C: Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000, 48:661-672.
20. Boon T, van der Bruggen P: Human tumor antigens recognized by T lymphocytes. The Journal of Experimental Medicine 1996, 183:725-729.
21. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo, implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996, 66:162-169.
22. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hod FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bahn A, Daley J, Neuberg D, Parry G, Rokowich J, Richards L, Drayer J, Berns A, Clift S, Dranoff G: Vaccination with irradiated autologous melanoma cells engineered to secrete human granolucyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998, 95:13141-13146.
23. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf S: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature 1998, 4:328-332.
24. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen presenting in vitro and in vivo. Journal of Experimental Medicine 1996, 184:465-472.
25. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccinated with the irradiated autologous prostate tumor cells engineered to secreted granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Research 1999, 59:5160-5168.
26. Kobayashi T, Yamanaka R, Homma J, Tsuchiya N, Yajima N, Yoshida S, Tanaka R: Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 2003, 52:632-637.
27. Griffioen M, Borghi M, Schrier PI, Osanto S, Schadendorf D: Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunol Immunother 2004, 53:715-722.
28. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E: Induction of tumor immunity and cytotoxic T lymphocytes responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Research 2000, 60:1028-1034.
29. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J: Induction of polyclonal prostate cancer-specific CTL using Dendritic cells transfected with amplified tumor RNA. The Journal of Immunology 2001, 166:2953-2960.
30. Grünebach F, Müller MR, Nencioni A, Brossart P: Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Therapy 2003, 10:367-374.
31. Hoerr I, Obst R, Rammensee HG, Jung G: In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology 2000, 30:1-7.
32. Seth D, Gorrell MD, McGuinness PH, Leo MA, Lieber CS, McCaugan GW, Haber PS: SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. J Biochem Biophzs Methods 2003, 55:53-66.
33. Wellenreuther R, Schupp I, Consortium TGDNA, Poutska A, Wiemann S: SMART amplification combined with cDNA size fractionation in order to obtain large full-length clones. BMC Genomics 2004, 5:36-44.
34. Yu J, Russell E: Structural and functional analysis of an mRNP complex that mediates the high stability of human β-globin mRNA. Molecular and Cellular Biology 2001, 21:5879-5888.
35. Wang Z, Day N, Trifillis P, Kiledjian M: An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro. Molecular and Cellular Biology 1999, 19:4552-4560.
36. Altschul SF, Gish W, Miller W, Meyers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol 1990, 215:403-410.
37. Draper MP, August PR, Connolly T, Packard B, Call KM: Efficient cloning of full-length cDNAs based on cDNA size fractionation. Genomics 2002, 79:603-607.
38. Wibe E, Paus E, Aamdal S: Neuron specific enolase (NSE) in serum of patients with malignant melanoma. Cancer Letters 1990, 52:29-31.
39. Kondoh N, Schweinfest CW, Henderson KW, Papas TS: Differential Expression of S19 Ribosomal-Protein, Laminin-Binding Protein, and Human Lymphocyte Antigen Class-I Messenger-Rnas Associated with Colon-Carcinoma Progression and Differentiation. Cancer Res 1992, 52:791-796.
40. Affymetrix's Eukaryotic Sample and Array Processing. http://www.affymetrix.com/support//downloads/manuls/ expression_s2_manual.pdf
41. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH: Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 1990, 87:1663-1667.
42. GNF Gene Expression Atlas.: [http://expression.gnf.org/cgi-bin/index.cgi].
43. Wang FL, Wang YB, Wong WK, Liu Y, Addivinola FJ, Liang P, Chen LB, Kantoff PW, Pardee AB: Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res 1996, 56:3634-3637.
44. Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J, Moskal JR: The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 2000, 156:191-198.
45. Standal T, Borset M, Sundan A: Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004, 26:179-184.
46. Jiang HP, Lin JJ, Tao J, Fisher PB: Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-beta. Oncogene 1997, 14:473-480.
47. Banerjee A: Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002, 293:598-601.
48. Adams SM, Sharp MGF, Walker RA, Brammar WJ, Varley JM: Differential Expression of Translation-Associated Genes in Benign and Malignant Human Breast-Tumors. Br J Cancer 1992, 65:65-71.
49. Friedman RS, Bangur CS, Zasloff EJ, Fan LQ, Wang TT, Watanabe Y, Kalos M: Molecular and immunological evaluation of the transcription factor SOX-4 as a lung tumor vaccine antigen. J Immunol 2004, 172:3319-3327.
50. Bommer UA, Thiele BJ: The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol 2004, 36:379-385.
51. Finch JS, Stjohn T, Krieg P, Bonham K, Smith HT, Fried VA, Bowden GT: Overexpression of 3 Ubiquitin Genes in Mouse Epidermal Tumors Is Associated with Enhanced Cellular Proliferation and Stress. Cell Growth Differ 1992, 3:269-278.